454 related articles for article (PubMed ID: 22404097)
1. Quinazoline derivatives as potential anticancer agents: a patent review (2007 - 2010).
Marzaro G; Guiotto A; Chilin A
Expert Opin Ther Pat; 2012 Mar; 22(3):223-52. PubMed ID: 22404097
[TBL] [Abstract][Full Text] [Related]
2. Quinazoline derivatives as anticancer drugs: a patent review (2011 - present).
Ravez S; Castillo-Aguilera O; Depreux P; Goossens L
Expert Opin Ther Pat; 2015 Jul; 25(7):789-804. PubMed ID: 25910402
[TBL] [Abstract][Full Text] [Related]
3. Recent development on naphthoquinone derivatives and their therapeutic applications as anticancer agents.
Tandon VK; Kumar S
Expert Opin Ther Pat; 2013 Sep; 23(9):1087-108. PubMed ID: 23651032
[TBL] [Abstract][Full Text] [Related]
4. Quinazoline and quinazolinone as important medicinal scaffolds: a comparative patent review (2011-2016).
Hameed A; Al-Rashida M; Uroos M; Ali SA; Arshia ; Ishtiaq M; Khan KM
Expert Opin Ther Pat; 2018 Apr; 28(4):281-297. PubMed ID: 29368977
[TBL] [Abstract][Full Text] [Related]
5. Quinazolines as Apoptosis Inducers and Inhibitors: A Review of Patent Literature.
Mehndiratta S; Sapra S; Singh G; Singh M; Nepali K
Recent Pat Anticancer Drug Discov; 2016; 11(1):2-66. PubMed ID: 26681186
[TBL] [Abstract][Full Text] [Related]
6. FMS-like tyrosine kinase 3 inhibitors: a patent review.
Lee J; Paek SM; Han SY
Expert Opin Ther Pat; 2011 Apr; 21(4):483-503. PubMed ID: 21323612
[TBL] [Abstract][Full Text] [Related]
7. Bestowal of Quinazoline Scaffold in Anticancer Drug Discovery.
Das R; Mehta DK; Dhanawat M
Anticancer Agents Med Chem; 2021; 21(11):1350-1368. PubMed ID: 32593282
[TBL] [Abstract][Full Text] [Related]
8. Inhibitors of JAK2 and JAK3: an update on the patent literature 2010 - 2012.
Dymock BW; See CS
Expert Opin Ther Pat; 2013 Apr; 23(4):449-501. PubMed ID: 23367873
[TBL] [Abstract][Full Text] [Related]
9. Discovery of 6-substituted 4-anilinoquinazolines with dioxygenated rings as novel EGFR tyrosine kinase inhibitors.
Li DD; Fang F; Li JR; Du QR; Sun J; Gong HB; Zhu HL
Bioorg Med Chem Lett; 2012 Sep; 22(18):5870-5. PubMed ID: 22901387
[TBL] [Abstract][Full Text] [Related]
10. Therapeutic progression of quinazolines as targeted chemotherapeutic agents.
Bansal R; Malhotra A
Eur J Med Chem; 2021 Feb; 211():113016. PubMed ID: 33243532
[TBL] [Abstract][Full Text] [Related]
11. Quinazoline compounds for antitumor treatment.
Solyanik GI
Exp Oncol; 2019 Mar; 41(1):3-6. PubMed ID: 30932417
[TBL] [Abstract][Full Text] [Related]
12. Imidazoline derivatives: a patent review (2006--present).
Guan X; Hu Y
Expert Opin Ther Pat; 2012 Nov; 22(11):1353-65. PubMed ID: 23003008
[TBL] [Abstract][Full Text] [Related]
13. Heat-shock protein 90 inhibitors as antitumor agents: a survey of the literature from 2005 to 2010.
Messaoudi S; Peyrat JF; Brion JD; Alami M
Expert Opin Ther Pat; 2011 Oct; 21(10):1501-42. PubMed ID: 21689065
[TBL] [Abstract][Full Text] [Related]
14. Recent developments on JAK2 inhibitors: a patent review.
Kiss R; Sayeski PP; Keserũ GM
Expert Opin Ther Pat; 2010 Apr; 20(4):471-95. PubMed ID: 20205617
[TBL] [Abstract][Full Text] [Related]
15. Taking quinazoline as a general support-Nog to design potent and selective kinase inhibitors: application to FMS-like tyrosine kinase 3.
Li WW; Chen JJ; Zheng RL; Zhang WQ; Cao ZX; Yang LL; Qing XY; Zhou LX; Yang L; Yu LD; Chen LJ; Wei YQ; Yang SY
ChemMedChem; 2010 Apr; 5(4):513-6. PubMed ID: 20140937
[No Abstract] [Full Text] [Related]
16. The association between anti-tumor potency and structure-activity of protein-kinases inhibitors based on quinazoline molecular skeleton.
Li Y; Xiao J; Zhang Q; Yu W; Liu M; Guo Y; He J; Liu Y
Bioorg Med Chem; 2019 Feb; 27(3):568-577. PubMed ID: 30600149
[TBL] [Abstract][Full Text] [Related]
17. Proteasome inhibitor patents (2010 - present).
Metcalf R; Scott LM; Daniel KG; Dou QP
Expert Opin Ther Pat; 2014 Apr; 24(4):369-82. PubMed ID: 24450483
[TBL] [Abstract][Full Text] [Related]
18. Anti-cancer therapeutic potential of quinazoline based small molecules via global upregulation of miRNAs.
Nahar S; Bose D; Kumar Panja S; Saha S; Maiti S
Chem Commun (Camb); 2014 May; 50(35):4639-42. PubMed ID: 24671295
[TBL] [Abstract][Full Text] [Related]
19. AMP-activated protein kinase modulators: a patent review (2006 - 2010).
Yun H; Ha J
Expert Opin Ther Pat; 2011 Jul; 21(7):983-1005. PubMed ID: 21548715
[TBL] [Abstract][Full Text] [Related]
20. Protein kinase CK2 inhibitors: a patent review.
Cozza G; Pinna LA; Moro S
Expert Opin Ther Pat; 2012 Sep; 22(9):1081-97. PubMed ID: 22908959
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
